Safinamide in neurological disorders and beyond: Evidence from preclinical and clinical studies

  title={Safinamide in neurological disorders and beyond: Evidence from preclinical and clinical studies},
  author={Himika Wasan and Devendra Singh and K H Reeta},
  journal={Brain Research Bulletin},
The discovery and development of safinamide, an alpha-aminoamide, has been a valuable addition to the existing clinical management of Parkinson's disease (PD). The journey of safinamide dates back to the year 1983, when an alpha-aminoamide called milacemide showed a weak anticonvulsant activity. Milacemide was then structurally modified to give rise to safinamide, which in turn produced robust anticonvulsant activity. The underlying mechanism behind this action of safinamide is attributed to… Expand
The Current Evidence for the Use of Safinamide for the Treatment of Parkinson's Disease
Its benefits in improving motor functions and fluctuations, and some non-motor symptoms, could have a valuable impact on patients’ quality of life (QoL), together with its safety profile. Expand
Ion Channels as New Attractive Targets to Improve Re-Myelination Processes in the Brain
The present review summarizes recent findings in the field to get further insights into physio-pathophysiological processes and possible therapeutic mechanisms of drug actions. Expand
Post Stroke Safinamide Treatment Attenuates Neurological Damage by Modulating Autophagy and Apoptosis in Experimental Model of Stroke in Rats.
Overall, the results demonstrated neuroprotective potential of safinamide via anti-oxidant, anti-inflammatory,Anti-apoptotic, and autophagy inducing properties and can be explored for repurposing in ischemic stroke after further exploration. Expand


An expert opinion on safinamide in Parkinson's disease
Savinamide is a promising investigational drug for PD with a novel mode of action, targeting both dopaminergic and glutaminergic systems, and potentially provides motor symptom control and neuroprotective effects. Expand
Ideal treatment in Parkinson’s disease (PD) aims at relieving symptoms and slowing disease progression. Of all remedies, levodopa remains the most effective for symptomatic relief, but the medicalExpand
Clinical Pharmacokinetics and Pharmacodynamics of Safinamide
The introduction of safinamide reflects a change of approach to drug development for anti-parkinsonian agents in that its broad spectrum of action corresponds to the multiple heterogeneous alterations of brain neurochemistry in PD, rather than being targeted at a single receptor type or neurochemical process. Expand
Pharmacokinetic drug evaluation of safinamide mesylate for the treatment of mid-to-late stage Parkinson’s disease
  • T. Müller
  • Medicine
  • Expert opinion on drug metabolism & toxicology
  • 2017
Savinamide will help to reduce dosing of levodopa but also of dopamine agonists during long term treatment in patients with Parkinson’s disease, as its pharmacological profile includes reversible monoamine oxidase B inhibition, blockage of voltage-dependent sodium channels, modulation of calcium channels and abnormal glutamate release. Expand
Safinamide: a new hope for Parkinson's disease?
Overall, safinamide can be considered to have potential antidyskinetic and neuroprotective effects and future trials and/or studies should be performed to provide further evidence for its potential as an anti-PD drug. Expand
Safinamide Modulates Striatal Glutamatergic Signaling in a Rat Model of Levodopa-Induced Dyskinesia
Findings suggest that the striatal glutamate-modulating component of safinamide’s activity may contribute to its clinical effects, where its long-term use as levodopa add-on therapy significantly improves motor function and “on” time without troublesome dyskinesia. Expand
Safinamide in the management of patients with Parkinson’s disease not stabilized on levodopa: a review of the current clinical evidence
Evidence suggests that safinamide is a good option for add-on therapy to carbidopa/levodopa in patients with advanced Parkinson’s disease with motor complications, but there is still insufficient evidence to recommend it as monotherapy or add- on therapy in patientswith early PD. Expand
Safinamide: First Global Approval
The milestones in the development of safinamide leading to its first approval for Parkinson’s disease are summarized. Expand
Safinamide for the treatment of Parkinson’s disease
Savinamide has been found to be a useful adjunctive to dopamine agonists in early PD and has been shown to increase time without increasing troublesome dyskinesias when used as an adjunct to levodopa in patients with advanced PD. Expand
Novel nondopaminergic targets for motor features of Parkinson's disease: Review of recent trials
Nondopaminergic drugs are not expected to replace dopaminergic strategies, but further development of these drugs will likely yield novel approaches with positive clinical implications. Expand